Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data

Por Rodriguez, Allan E, DeJesus, Edwin, Williams, Vanessa, Irlbeck, David, Ross, Lisa, Ha, Belinda, Lancaster, Charles T
Publicado em 2010

Safety and Efficacy of Enfuvirtide in Combination with Darunavir-Ritonavir and an Optimized Background Regimen in Treatment-Experienced Human Immunodeficiency Virus-Infected Patien...

Por DeJesus, Edwin, Gottlieb, Michael S., Gathe, Joseph C., Greenberg, Michael L., Guittari, Carol Jean, Zolopa, Andrew R.
Publicado em 2008

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-In...

Por Jacobson, Jeffrey M., Kuritzkes, Daniel R., Godofsky, Eliot, DeJesus, Edwin, Larson, Jeffrey A., Weinheimer, Steven P., Lewis, Stanley T.
Publicado em 2009

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice...

Por Kumar, Princy N, Salvato, Patricia, LaMarca, Anthony, DeJesus, Edwin, Patel, Parul, McClernon, Daniel, Florance, Allison, Shaefer, Mark S
Publicado em 2009

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice

Por Lackey, Philip, Mills, Anthony, Carpio, Felix, Hsu, Ricky, DeJesus, Edwin, Pierone, Gerald, Henegar, Cassidy, Fusco, Jennifer, Fusco, Gregory, Wohlfeiler, Mike
Publicado no Clin Drug Investig (2016)

Interaction between Fosamprenavir, with and without Ritonavir, and Nevirapine in Human Immunodeficiency Virus-Infected Subjects

Por DeJesus, Edwin, Piliero, Peter J., Summers, Kim, Wire, Mary Beth, Stein, Daniel S., Masterman, Amanda, Lou, Yu, Min, Sherene S., Shelton, Mark J.
Publicado em 2006

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

Por Thompson, Melanie, Saag, Michael, DeJesus, Edwin, Gathe, Joseph, Lalezari, Jay, Landay, Alan L., Cade, Jerry, Enejosa, Jeffrey, Lefebvre, Eric, Feinberg, Judith
Publicado no AIDS (2016)

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

Por Gallant, Joel E., Thompson, Melanie, DeJesus, Edwin, Voskuhl, Gene W., Wei, Xuelian, Zhang, Heather, White, Kirsten, Cheng, Andrew, Quirk, Erin, Martin, Hal
Publicado no J Acquir Immune Defic Syndr (2017)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

Por Smith, Kimberly Y, Weinberg, Winkler G, DeJesus, Edwin, Fischl, Margaret A, Liao, Qiming, Ross, Lisa L, Pakes, Gary E, Pappa, Keith A, Lancaster, C Tracey
Publicado em 2008

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infec...

Por Kumar, Princy, DeJesus, Edwin, Huhn, Gregory, Sloan, Louis, Small, Catherine Butkus, Edelstein, Howard, Felizarta, Franco, Hao, Ritche, Ross, Lisa, Stancil, Britt, Pappa, Keith, Ha, Belinda
Publicado em 2013

Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected...

Por Ross, Lisa L., Weinberg, Winkler G., DeJesus, Edwin, Fischl, Margaret A., Horton, Joseph H., Pappa, Keith A., Lancaster, C. Tracey, Pakes, Gary E., Smith, Kimberly Y.
Publicado em 2010

Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial

Por Wohl, David A., Bhatti, Laveeza, Small, Catherine B., Edelstein, Howard, Zhao, Henry H., Margolis, David A., DeJesus, Edwin, Weinberg, Winkler G., Ross, Lisa L., Shaefer, Mark S.
Publicado em 2014

HIV-1 Transmission Patterns in Antiretroviral Therapy-Naïve, HIV-Infected North Americans Based on Phylogenetic Analysis by Population Level and Ultra-Deep DNA Sequencing

Por Ross, Lisa L., Horton, Joseph, Hasan, Samiul, Brown, James R., Murphy, Daniel, DeJesus, Edwin, Potter, Martin, LaMarca, Anthony, Melendez-Rivera, Ivan, Ward, Douglas, Uy, Jonathon, Shaefer, Mark S.
Publicado em 2014

Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologi...

Por Daar, Eric, DeJesus, Edwin, Ruane, Peter, Crofoot, Gordon, Oguchi, Godson, Creticos, Catherine, Rockstroh, Jurgen K, Molina, Jean-Michel, Koenig, Ellen, Liu, Ya-Pei, Andreatta, Kristen, Graham, Hiba, Cheng, Andrew, Martin, Hal, Quirk, Erin
Publicado no Open Forum Infect Dis (2017)

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

Por Keiser, Philip H, Sension, Michael G, DeJesus, Edwin, Rodriguez, Allan, Olliffe, Jeffrey F, Williams, Vanessa C, Wakeford, John H, Snidow, Jerry W, Shachoy-Clark, Anne D, Fleming, Julie W, Pakes, Gary E, Hernandez, Jaime E
Publicado em 2005

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase...

Por Choi, Jun Yong, Sungkanuparph, Somnuek, Anekthananon, Thanomsak, Sax, Paul, DeJesus, Edwin, Edelstein, Howard, Nelson, Mark, DeMorin, Jennifer, Liu, Hui C., Swamy, Raji, Bahn, Joonwoo, Hwang, SunJin, Yang, SangYoun, Ng, Christopher, Piontkowsky, David
Publicado no Infect Chemother (2016)

Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study

Por Berkowitz, Elchonon M., Moyle, Graeme, Stellbrink, Hans-Jürgen, Schürmann, Dirk, Kegg, Stephen, Stoll, Matthias, El Idrissi, Mohamed, Oostvogels, Lidia, Heineman, Thomas C., Brockmeyer, Norbert, deJesus, Edwin, Esser, Stefan, Hawkins, Trevor, Lalezari, Jacob, Orkin, Chloe, Schneider, Stefan
Publicado no J Infect Dis (2015)

Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing

Por Melikian, George L., Rhee, Soo-Yon, Varghese, Vici, Porter, Danielle, White, Kirsten, Taylor, Jonathan, Towner, William, Troia, Paolo, Burack, Jeffrey, DeJesus, Edwin, Robbins, Gregory K., Razzeca, Kristin, Kagan, Ron, Liu, Tommy F., Fessel, W. Jeffrey, Israelski, Dennis, Shafer, Robert W.
Publicado em 2014

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

Por Gane, Edward J., DeJesus, Edwin, Janczewska, Ewa, George, Jacob, Diago, Moises, Da Silva, Mariliza Hendrique, Reesink, Henk, Nikitin, Igor, Hinrichsen, Holger, Bourgeois, Stefan, Ferenci, Peter, Shukla, Umesh, Kalmeijer, Ronald, Lenz, Oliver, Fevery, Bart, Corbett, Chris, Beumont, Maria, Jessner, Wolfgang
Publicado no BMC Infect Dis (2017)

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Por Gulick, Roy M., Lalezari, Jacob, Goodrich, James, Clumeck, Nathan, DeJesus, Edwin, Horban, Andrzej, Nadler, Jeffrey, Clotet, Bonaventura, Karlsson, Anders, Wohlfeiler, Michael, Montana, John B., McHale, Mary, Sullivan, John, Ridgway, Caroline, Felstead, Steve, Dunne, Michael W., van der Ryst, Elna, Mayer, Howard
Publicado em 2008